Orforglipron: Research & Studies

Research Overview#

Orforglipron has been evaluated in a substantial clinical development program spanning Phase 1 through Phase 3 trials. The evidence base includes first-in-human pharmacokinetic studies, dose-ranging Phase 2 trials in both obesity and type 2 diabetes, and large Phase 3 registration trials. The ATTAIN program (obesity) and ACHIEVE program (type 2 diabetes) collectively enrolled thousands of participants.

The evidence level is classified as high based on multiple randomized, placebo-controlled Phase 3 trials with clinically meaningful endpoints. However, the absence of active comparator data and cardiovascular outcomes trials are notable gaps.

Phase 1 Development#

Phase 1a: Healthy Volunteers#

The first-in-human Phase 1a study (Pratt et al., 2023; PMID 37344954) evaluated single and multiple ascending doses of orforglipron in healthy participants. The study established the pharmacokinetic profile that would support once-daily oral dosing: dose-proportional exposure with a half-life of 25-35 hours after single doses, extending to 48-68 hours at steady state due to accumulation.

Gastrointestinal adverse events (nausea, vomiting) were dose-dependent and generally mild, consistent with on-target GLP-1 receptor activation.

Phase 1b: Type 2 Diabetes#

A Phase 1b multiple-ascending-dose study in patients with type 2 diabetes confirmed the PK profile observed in healthy volunteers and demonstrated dose-dependent reductions in fasting and postprandial glucose, providing proof-of-concept for glycemic efficacy.

Phase 2 Obesity Trial#

The pivotal Phase 2 obesity trial (Frias et al., 2023; PMID 37351564) was published in the New England Journal of Medicine and provided the first robust efficacy data for orforglipron in weight management. The trial randomized 272 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition to orforglipron 12, 24, 36, or 45 mg daily or placebo for 36 weeks.

Key Findings#

At week 36, mean body weight reductions were:

• 12 mg: -9.4%
• 24 mg: -10.4%
• 36 mg: -12.6%
• 45 mg: -14.7%
• Placebo: -2.3%

The 45 mg dose was not advanced to Phase 3 due to tolerability concerns. Weight loss was progressive and had not fully plateaued at 36 weeks, suggesting additional weight reduction with longer treatment duration.

Significance#

These Phase 2 results positioned orforglipron as the first oral non-peptide GLP-1 agonist with weight loss efficacy approaching that of injectable semaglutide, generating substantial interest in the possibility of an oral alternative to injections.

Phase 3 ATTAIN Program (Obesity)#

ATTAIN-1: Obesity Without Diabetes#

The ATTAIN-1 trial (Aronne et al., NEJM 2025; PMID 40960239) was the pivotal Phase 3 trial for the obesity indication, enrolling 3,127 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with comorbidities. Participants were randomized to orforglipron 6, 12, or 36 mg daily or placebo for 72 weeks.

Primary endpoint results (mean body weight change at 72 weeks):

• 6 mg: -7.5% (95% CI -8.2 to -6.8)
• 12 mg: -8.4% (95% CI -9.1 to -7.7)
• 36 mg: -11.2% (95% CI -12.0 to -10.4)
• Placebo: -2.1% (95% CI -2.8 to -1.4)
• All comparisons P<0.001 versus placebo

Weight loss thresholds (36 mg vs placebo):

• 5% or more: 73.2% vs 33.8%
• 10% or more: 54.6% vs 12.9%
• 15% or more: 36.0% vs 5.9%
• 20% or more: 18.4% vs 2.8%

Secondary endpoints demonstrated significant improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol.

ATTAIN-2: Obesity With Type 2 Diabetes#

ATTAIN-2 (Horn et al., Lancet 2025; PMID 41275875) evaluated orforglipron in adults with both obesity and type 2 diabetes, a population known to have attenuated weight loss responses to GLP-1 agonists. The trial was conducted across 136 sites in 10 countries.

At 72 weeks, the 36 mg dose achieved:

• Mean weight loss of 10.5% (vs placebo)
• HbA1c reduction of 1.8% from baseline of 8.1%
• Significant improvements in cardiometabolic risk factors

The lower weight loss compared to ATTAIN-1 (10.5% vs 11.2%) is consistent with the well-established observation that type 2 diabetes attenuates pharmacological weight loss.

Phase 3 ACHIEVE Program (Type 2 Diabetes)#

ACHIEVE-1: Early Type 2 Diabetes#

The ACHIEVE-1 trial evaluated orforglipron as an add-on to metformin in patients with early type 2 diabetes. Orforglipron demonstrated statistically superior glycemic control at all dose levels, with HbA1c reductions and a safety profile consistent with injectable GLP-1 therapies.

Cross-Trial Context#

Comparison with Phase 2 Results#

The Phase 3 ATTAIN-1 results (11.2% weight loss at 36 mg, 72 weeks) were lower than the Phase 2 results (14.7% at 45 mg, 36 weeks). This attenuation likely reflects the use of a lower maximum dose (36 mg vs 45 mg), a larger and more diverse population, and the fact that weight loss may plateau after 36 weeks. The 36 mg dose in Phase 2 produced 12.6% weight loss at 36 weeks.

Comparison with Injectable GLP-1 Agonists#

Cross-trial comparisons (not head-to-head) suggest:

• Semaglutide 2.4 mg (Wegovy): 14.9% at 68 weeks (STEP 1)
• Orforglipron 36 mg: 11.2% at 72 weeks (ATTAIN-1)
• Tirzepatide 15 mg (Zepbound): 20.9% at 72 weeks (SURMOUNT-1)

Orforglipron's weight loss is lower than injectable comparators, but its oral, non-peptide nature provides a fundamentally different convenience and manufacturing profile.

Evidence Quality Assessment#

Key Research Gaps#

1. No cardiovascular outcomes data: Unlike semaglutide (SELECT trial), no CVOT has been completed for orforglipron. This is a significant gap given that cardiovascular benefit is increasingly expected for anti-obesity medications.

2. No active comparator trials: Direct comparisons with semaglutide or tirzepatide are needed to establish the relative efficacy of oral orforglipron versus injectable alternatives.

3. Long-term data: The longest controlled data span 72 weeks. Weight maintenance, long-term safety, and durability of metabolic improvements beyond this period are unknown.

4. Body composition: The proportion of weight lost as fat versus lean mass has not been reported, an increasingly important consideration for anti-obesity therapies.

5. Specific populations: Data in adolescents, elderly, and patients with CKD, NASH, or heart failure are limited or absent.

Related Reading#

• Orforglipron overview and research guide
• Orforglipron dosing protocols
• Orforglipron molecular structure